Sponsor:
Vericel Corporation
Code:
NCT03588975
Conditions
Chondral Defect
Osteochondritis Dissecans (OCD)
Articular Cartilage Defect
Articular Cartilage Disorder of Knee
Eligibility Criteria
Sex: All
Age: 10 - 17
Healthy Volunteers: Not accepted
Interventions
MACI
microfracture
Brief summary:
Conditions
Chondral Defect
Osteochondritis Dissecans (OCD)
Articular Cartilage Defect
Articular Cartilage Disorder of Knee
Study ID
NCT03588975
Start date
Oct 24, 2018
Status verified date
Jun, 2026
Completion date
Feb, 2030
Anticipated
Primary completion date
Feb, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 10 - 17
Healthy Volunteers: Not accepted
Enrollment
45 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: MACI
other: microfracture
Interventions
MACI
microfracture
Primary outcome measure
Central contacts
Locations
Stanford University
Recruiting
Palo Alto, California, United States, 94304
Shriner's Hospital for Children Northern California
Recruiting
Sacramento, California, United States, 95817
University of California Davis Health
Recruiting
Sacramento, California, United States, 95817
Ochsner Sports Medicine Institute
Recruiting
New Orleans, Louisiana, United States, 70121
Johns Hopkins Outpatient Center
Recruiting
Baltimore, Maryland, United States, 21224
University of Michigan
Recruiting
Ann Arbor, Michigan, United States, 48106
Akron Children's Hospital
Recruiting
Akron, Ohio, United States, 44308
The Ohio State University Jameson Crane Sports Medicine Institute
Recruiting
Columbus, Ohio, United States, 43202
Children's Hospital of Philadelphia
Recruiting
Philadelphia, Pennsylvania, United States, 19104
Penn Sports Medicine Center
Recruiting
Philadelphia, Pennsylvania, United States, 19104
Medical College of Wisconsin
Recruiting
Milwaukee, Wisconsin, United States, 53201
Sponsor
Vericel Corporation
Last update posted
Jun 24, 2026
Last verified
Jun, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Vericel Corporation on 2026-06-24.